Stability and release kinetics of an advanced gliclazide-cholic acid formulation: The Use of artificial-cell microencapsulation in slow release targeted oral delivery of antidiabetics

Journal of Pharmaceutical Innovation

Volumn 9, Issue 2, 2014, Pages 150-157

  Mooranian, Armin ^a   Negrulj, Rebecca ^a   Mathavan, Sangeetha ^a   Martinez, Jorge ^a   Sciarretta, Jessica ^a   Chen Tan, Nigel ^b   Mukkur, T K ^a   Mikov, Momir ^c,d   Lalic Popovic, Mladena ^c   Stojancěvić, Maja ^c   Golocorbin Kon, Svetlana ^c,d   Al Salami, Hani ^a  

^a CURTIN UNIVERSITY   (Australia)

^b CURTIN UNIVERSITY   (Australia)

^c UNIVERSITY OF NOVI SAD   (Serbia)

^d UNIVERSITY OF MONTENEGRO   (Montenegro)

Author keywords

Artificial cell microencapsulation; Bile acid; Diabetes; Gliclazide

Indexed keywords

ALGINIC ACID; CHOLIC ACID; GLICLAZIDE;

ARTICLE; ARTIFICIAL CELL; CONTROLLED STUDY; DRUG BIOAVAILABILITY; DRUG DELIVERY SYSTEM; DRUG FORMULATION; DRUG RELEASE; DRUG SOLUBILITY; DRUG STABILITY; EXCIPIENT COMPATIBILITY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; MICROCAPSULE; MICROENCAPSULATION; MOISTURE; PARTICLE SIZE; PH; PRIORITY JOURNAL; TEMPERATURE; ZETA POTENTIAL;

EID: 84905722565     PISSN: 18725120     EISSN: 19398042     Source Type: Journal    
DOI: 10.1007/s12247-014-9182-5     Document Type: Article

References (45)

1. Barbeau WE, Bassaganya-Riera J, Hontecillas R. Putting the pieces of the puzzle together - a series of hypotheses on the etiology and pathogenesis of type 1 diabetes. Med Hypotheses. 2007;68(3):607-19. (Pubitemid 46037970)
2. Moore, P.A., J.C. Zgibor, and A.P. Dasanayake, Diabetes: a growing epidemic of all ages. J Am Dent Assoc, 2003. 134 Spec No: p. 11S-15S.
3. Cani PD et al. Selective increases of bifidobacteria in gut microflora improve high-fat-diet-induced diabetes in mice through a mechanism associated with endotoxaemia. Diabetologia. 2007;50(11):2374-83. (Pubitemid 47512397)
4. Campbell DB, Lavielle R, Nathan C. The mode of action and clinical pharmacology of gliclazide: a review. Diabetes Res Clin Pract. 1991;14 Suppl 2:S21-36.
5. Palmer KJ, Brogden RN. Gliclazide. An update of its pharmacological properties and therapeutic efficacy in non-insulin-dependent diabetes mellitus. Drugs. 1993;46(1):92-125. (Pubitemid 23232408)
6. Schernthaner, G. and . Gliclazide modified release: a critical review of pharmacodynamic, metabolic, and vasoprotective effects.Metabolism: Clinical and Experimental, 2003. 52(8 suppl.1): p. 29 - 34.
7. Al-Kassas RS, Al-Gohary OM, Al-Faadhel MM. Controlling of systemic absorption of gliclazide through incorporation into alginate beads. Int J Pharm. 2007;341(1-2):230-7. (Pubitemid 47088107)
8. Hong SS et al. Accelerated oral absorption of gliclazide in human subjects from a soft gelatin capsule containing a PEG 400 suspension of gliclazide. J Control Release. 1998;51(2-3):185-92. (Pubitemid 28252870)
9. Al-Salami H et al. Gliclazide reduces MKC intestinal transport in healthy but not diabetic rats. Eur J Drug Metab Pharmacokinet. 2009;34(1):43-50.
10. Mikov M et al. Pharmacokinetics and hypoglycaemic effect of 3 alpha, 7 alpha-dihydroxy-12-oxo-5beta-cholanate (MKC) in diabetic rat. Febs J. 2006;273:210.
11. Al-Salami H et al. Influence of the semisynthetic bile acid (MKC) on the ileal permeation of gliclazide in healthy and diabetic rats. Methods Find Exp Clin Pharmacol. 2008;30(2):107-13. (Pubitemid 351738270)
12. Al-Salami H et al. Probiotic treatment proceeded by a single dose of bile acid and gliclazide exert the most hypoglycemic effect in Type 1 diabetic rats. Med Hypothesis Res. 2008;4(2):93-101.
13. Al-Salami H et al. Probiotics decreased the bioavailability of the bile acid analog, monoketocholic acid, when coadministered with gliclazide, in healthy but not diabetic rats. Eur J Drug Metab Pharmacokinet. 2012;37(2):99-108.
14. Mladena Lalić-Popović, Velibor Vasović, Boris Milijašević, Svetlana Goločorbin-Kon, Hani Al-Salami, Momir Mikov. Deoxycholic acid as a modifier of the permeation of gliclazide through the blood brain barrier of a Rat. J Diabetes Res. 2013:1-9.
15. Mikov M et al. The influence of 3alpha,7alpha-dihydroxy-12-keto- 5beta-cholanate on gliclazide pharmacokinetics and glucose levels in a rat model of diabetes. Eur J Drug Metab Pharmacokinet. 2008;33(3):137-42.
16. Yu CYet al. Compositemicroparticle drug delivery systems based on chitosan, alginate and pectin with improved pH-sensitive drug release property. Colloids Surf B Biointerfaces. 2009;68(2):245-9.
17. Mitrevej A et al. Multiunit controlled-release diclofenac sodium capsules using complex of chitosan with sodium alginate or pectin. Pharma Dev Technol. 2001;6(3):385-92. (Pubitemid 32678244)
18. Livnat M, Beyar R, Seliktar D. Endoluminal hydrogel films made of alginate and polyethylene glycol: physical characteristics and drug-eluting properties. J Biomed Mater Res A. 2005;75(3):710-22. (Pubitemid 47233455)
19. Takka S, Acarturk F. Calcium alginate microparticles for oral administration: I: Effect of sodium alginate type on drug release and drug entrapment efficiency. J Microencapsul. 1999;16(3):275-90. (Pubitemid 29191812)
20. Storz H et al. Physicochemical features of ultra-high viscosity alginates. Carbohydr Res. 2009;344(8):985-95.
21. Lee HYet al. Influence of viscosity and uronic acid composition of alginates on the properties of alginate films and microspheres produced by emulsification. J Microencapsul. 2006;23(8):912-27.
22. Tapia-Albarran M, Villafuerte-Robles L. Effect of formulation and process variables on the release behavior of amoxicillin matrix tablets. Drug Dev Ind Pharm. 2004;30(8):901-8. (Pubitemid 39362873)
23. Prajapati S et al. Design and development of gliclazide mucoadhesive microcapsules: in vitro and in vivo evaluation. AAPS PharmSciTech. 2008;9(1):224-30.
24. Takka S, Cali AG. Bile salt-reinforced alginate-chitosan beads. Pharm Dev Technol. 2012;17(1):23-9.
25. El-Enany N. Spectrofluorimetric and spectrophotometric determination of gliclazide in pharmaceuticals by derivatization with 4-chloro-7-nitrobenzo-2- oxa-1,3-diazole. J AOAC Int. 2003;86(2):209- 14.
26. Barakat NS, Shazly GA, Almedany AH. Influence of polymer blends on the characterization of gliclazide-encapsulated into poly (epsiloncaprolactone) microparticles. Drug Dev Ind Pharm. 2013;39(2):352-62.
27. Singh B, Sharma DK, Gupta A. The controlled and sustained release of a fungicide from starch and alginate beads. J Environ Sci Health B. 2009;44(2):113-22.
28. Dima C, Cotârleţ M, Alexe P, Dima Ş. Microencapsulation of essential oil of pimento [ Pimenta dioica (L) Merr.] by chitosan/kcarrageenan complex coacervation method. Innovative Food Science & Emerging Technologies, 2014;22:203-211.
29. Jyothi NVN et al. Microencapsulation techniques, factors influencing encapsulation efficiency. J Microencapsul. 2010;27(3): 187-97.
30. Al-Salami H et al. Probiotic treatment reduces blood glucose levels and increases systemic absorption of gliclazide in diabetic rats. Eur J Drug Metab Pharmacokinet. 2008;33(2):101-6.
31. Al-Salami H et al. Influence of the semisynthetic bile acid (MKC) on the ileal permeation of gliclazide in healthy and diabetic rats. Pharmacol Rep. 2008;60(4):532-41.
32. Al-Salami H et al. Probiotic Pre-treatment reduces gliclazide permeation (ex vivo) in healthy rats but increases it in diabetic rats to the level seen in untreated healthy rats. Arch Drug Inf. 2008;1(1):35-41.
33. Bakatselou V, Oppenheim RC, Dressman JB. Solubilization and wetting effects of bile salts on the dissolution of steroids. Pharm Res. 1991;8(12):1461-9.
34. Luner PE. Wetting properties of bile salt solutions and dissolution media. J Pharm Sci. 2000;89(3):382-95. (Pubitemid 30152438)
35. Martoni C et al. Microencapsulated bile salt hydrolase producing Lactobacillus reuteri for oral targeted delivery in the gastrointestinal tract. Appl Microbiol Biotechnol. 2008;81(2):225-33.
36. Lalic-Popovic M et al. Deoxycholic acid as a modifier of the permeation of gliclazide through the blood brain barrier of a rat. J Diabetes Res. 2013;2013:598603.
37. Pavlovic N, Stankov K, Mikov M. Probiotics-interactions with bile acids and impact on cholesterol metabolism. Appl Biochem Biotechnol. 2012;168(7):1880-95.
38. Raskovic A et al. Effect of stevioside and sodium salt of monoketocholic acid on glycemia in normoglycemic and diabetic rats. Eur J Drug Metab Pharmacokinet. 2008;33(1):17-22. (Pubitemid 351629149)
39. Yang L et al. Physicochemical and biological characterization of monoketocholic acid, a novel permeability enhancer. Mol Pharm. 2009;6(2):448-56.
40. Bajpai J, Bajpai A, Mishra S. Dynamics of controlled release of potassium nitrate from a highly swelling binary biopolymeric blend of alginate and pectin. J Macromol Sci Part A: Pure Appl Chem. 2006;43(1):165-86. (Pubitemid 43102698)
41. Pasparakis G, Bouropoulos N. Swelling studies and in vitro release of verapamil from calcium alginate and calcium alginate-chitosan beads. Int J Pharm. 2006;323(1):34-42. (Pubitemid 44397368)
42. Wee S, Gombotz WR. Protein release from alginate matrices. Adv Drug Deliv Rev. 1998;31(3):267-85. (Pubitemid 28191869)
43. Anal AK et al. Chitosan-alginate multilayer beads for gastric passage and controlled intestinal release of protein. Drug Dev Ind Pharm. 2003;29(6):713-24. (Pubitemid 36835163)
44. Anal AK, Stevens WF. Chitosan-alginate multilayer beads for controlled release of ampicillin. Int J Pharm. 2005;290(1):45-54. (Pubitemid 40139043)
45. Nochos A, Douroumis D, Bouropoulos N. In vitro release of bovine serum albumin from alginate/HPMC hydrogel beads. Carbohydr Polym. 2008;74(3):451-7.